NFKB1 and breast carcinoma: In particular, it has been recently demonstrated that dithiolethione derivatives, in addition to the antiangiogenic and tumor suppressor PP2A activation properties37–39, inhibited NF-κB transcriptional activity via a covalent reaction, leading to the formation of a disulfide bond with the NF-κB p50 and p65 subunits to inhibit DNA binding in human estrogen receptor–negative breast cancer cells.33